ten years ago you could have bought regenron, speculation, five bucks. what would happen with that $500? how about this? a gain of roughly 9,900%. not a double, not a triple. not a quadruple. regenron is a ten-bagger but you couldn't have gotten in on that gain if you hadn't taken a risk in 2005 and bought a company with no profits and only the promises of a ceo that things would work out. regenron worked out in a major way but many small cap biotechs have done long and lost you money over a short period of time. you won't always identify who the winners in this space but that's okay as long as you cast a wide net and speculate, taking small positions in ten of these speculative bio techs, nine of them are going to zero. as long as the tenth was one regenron, you still would have made a monster gain. there should only be one small part of your diversified "mad money" portfolio but it belong there because the risk reward of trying to find speculative winners makes sense when you're young. for older investors, though, speculation is much more risky and i r

. >> so we've seen this happen at least once before with amgen and regenron's cholesterol drugs knownpcsk 9 inhibitors. amgen says it's about two years away before they test this new drug in humans. >> are they the only ones on to this? >> they are the ones who have identified this gene but since they published in the the "new england journal of medicine" the doors are open and anybody can start developing drugs targeting this gene mutation. >> i wonder if this is the first time something like this would be attempted. what kind of peres accident there for identifying and trying to mimic a gene like this? >> drug companies are doing it many much mar targeted ways. region ron has an effort but in the past it's been on an academic level. for instance these cholesterol drugs, this mutation was discovered at the university of texas that people naturally had a lower heart attack and heart disease risk who had this pcsk-9 regeneration. it takes a long time to develop the drugs but they've seen they can genetically validate the targets and they're starting to do it in house. people are excite